Comparative Pharmacology
Head-to-head clinical analysis: CYANOCOBALAMIN versus DV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYANOCOBALAMIN versus DV.
CYANOCOBALAMIN vs DV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyanocobalamin is a synthetic form of vitamin B12 that is converted to active coenzymes methylcobalamin and adenosylcobalamin. These coenzymes are essential for DNA synthesis, myelin formation, and hematopoiesis. Methylcobalamin acts as a cofactor for methionine synthase, converting homocysteine to methionine, while adenosylcobalamin is a cofactor for methylmalonyl-CoA mutase, converting methylmalonyl-CoA to succinyl-CoA.
Nucleoside reverse transcriptase inhibitor; inhibits HIV-1 reverse transcriptase by competing with natural deoxynucleotides and causing chain termination after incorporation into viral DNA.
1000 mcg IM once daily for 7 days, then 1000 mcg IM once weekly for 4 weeks, then 1000 mcg IM once monthly. Oral: 1000-2000 mcg PO once daily.
2 mg/kg IV every 8 hours for 14 days; or 2 mg/kg IM every 8 hours for 14 days; or 1.5 mg/kg IV every 6 hours for 14 days.
None Documented
None Documented
Clinical Note
moderateColchicine + Cyanocobalamin
"The serum concentration of Cyanocobalamin can be decreased when it is combined with Colchicine."
Clinical Note
moderateChloramphenicol + Cyanocobalamin
"The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chloramphenicol."
Approximately 6 days (400 h) in plasma; tissue stores extend terminal half-life to 40-90 days
Terminal elimination half-life is 3-5 hours in healthy adults; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (50-90% as unchanged drug); biliary/fecal (minor, <10%)
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for approximately 5-10%.
Category C
Category C
Vitamin Supplement
Vitamin Supplement